Zonisamide in the management of epilepsy in the elderly
Andrea Romigi,1,2 Eti A Femia,3 Cinzia Fattore,4 Giuseppe Vitrani,1 Giancarlo Di Gennaro,1 Valentina Franco4 1Istituto Neurologico Mediterraneo, IRCCS Neuromed, Pozzilli (IS), Italy; 2Neurophysiopathology Department, University of Rome Tor Vergata, Rome, Italy; 3Dipartimento di Scienze della Salute...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/4d0c107fc9f74a6c89b7637cc8150e83 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:4d0c107fc9f74a6c89b7637cc8150e83 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:4d0c107fc9f74a6c89b7637cc8150e832021-12-02T03:57:59ZZonisamide in the management of epilepsy in the elderly1178-1998https://doaj.org/article/4d0c107fc9f74a6c89b7637cc8150e832015-06-01T00:00:00Zhttps://www.dovepress.com/zonisamide-in-the-management-of-epilepsy-innbspthenbspelderly-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Andrea Romigi,1,2 Eti A Femia,3 Cinzia Fattore,4 Giuseppe Vitrani,1 Giancarlo Di Gennaro,1 Valentina Franco4 1Istituto Neurologico Mediterraneo, IRCCS Neuromed, Pozzilli (IS), Italy; 2Neurophysiopathology Department, University of Rome Tor Vergata, Rome, Italy; 3Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milano, Italy; 4Clinical Trial Centre & Antiepileptic Drugs, C. Mondino National Neurological Institute, Pavia, Italy Abstract: Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed. Keywords: zonisamide, elderly, epilepsy, safety, efficacyRomigi AFemia EAFattore CVitrani GDi Gennaro GFranco VDove Medical PressarticlezonisamideelderlyepilepsysafetyefficacyGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 10, Pp 931-937 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
zonisamide elderly epilepsy safety efficacy Geriatrics RC952-954.6 |
| spellingShingle |
zonisamide elderly epilepsy safety efficacy Geriatrics RC952-954.6 Romigi A Femia EA Fattore C Vitrani G Di Gennaro G Franco V Zonisamide in the management of epilepsy in the elderly |
| description |
Andrea Romigi,1,2 Eti A Femia,3 Cinzia Fattore,4 Giuseppe Vitrani,1 Giancarlo Di Gennaro,1 Valentina Franco4 1Istituto Neurologico Mediterraneo, IRCCS Neuromed, Pozzilli (IS), Italy; 2Neurophysiopathology Department, University of Rome Tor Vergata, Rome, Italy; 3Dipartimento di Scienze della Salute, Università degli Studi di Milano, Milano, Italy; 4Clinical Trial Centre & Antiepileptic Drugs, C. Mondino National Neurological Institute, Pavia, Italy Abstract: Zonisamide (ZNS), a second-generation antiepileptic drug, indicated as add-on treatment of focal epilepsy, has been recently approved as monotherapy for the treatment of partial seizures in adults affected by newly diagnosed epilepsy in Europe. Evidence on the efficacy and tolerability of antiepileptic drugs in the elderly is still lacking as these patients are frequently excluded from clinical trials. Here, a comprehensive overview of available data regarding the use of ZNS in the treatment of epilepsy in elderly people is provided. In a pooled analysis conducted in patients aged ≥65 years, no new/unexpected safety findings have emerged. Few data from uncontrolled investigations suggest that ZNS may be effective and well tolerated when administered as monotherapy or adjunctive antiepileptic treatment in the elderly. However, evidence from these observational studies is less than satisfactory, and randomized controlled trials focused on these patients are still needed. Keywords: zonisamide, elderly, epilepsy, safety, efficacy |
| format |
article |
| author |
Romigi A Femia EA Fattore C Vitrani G Di Gennaro G Franco V |
| author_facet |
Romigi A Femia EA Fattore C Vitrani G Di Gennaro G Franco V |
| author_sort |
Romigi A |
| title |
Zonisamide in the management of epilepsy in the elderly |
| title_short |
Zonisamide in the management of epilepsy in the elderly |
| title_full |
Zonisamide in the management of epilepsy in the elderly |
| title_fullStr |
Zonisamide in the management of epilepsy in the elderly |
| title_full_unstemmed |
Zonisamide in the management of epilepsy in the elderly |
| title_sort |
zonisamide in the management of epilepsy in the elderly |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/4d0c107fc9f74a6c89b7637cc8150e83 |
| work_keys_str_mv |
AT romigia zonisamideinthemanagementofepilepsyinnbspthenbspelderly AT femiaea zonisamideinthemanagementofepilepsyinnbspthenbspelderly AT fattorec zonisamideinthemanagementofepilepsyinnbspthenbspelderly AT vitranig zonisamideinthemanagementofepilepsyinnbspthenbspelderly AT digennarog zonisamideinthemanagementofepilepsyinnbspthenbspelderly AT francov zonisamideinthemanagementofepilepsyinnbspthenbspelderly |
| _version_ |
1718401484242026496 |